Trevena Inc (TRVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Trevena Inc (TRVN) has a cash flow conversion efficiency ratio of 0.193x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.50 Million) by net assets ($-23.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TRVN equity to assets ratio to measure how much of total assets are equity-financed.
Trevena Inc - Cash Flow Conversion Efficiency Trend (2011–2023)
This chart illustrates how Trevena Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Trevena Inc (TRVN) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Trevena Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trevena Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gaucho Group Holdings, Inc.
NASDAQ:VINOQ
|
-0.853x |
|
PHSC PLC
LSE:PHSC
|
-0.049x |
|
Sotherly Hotels Inc Series B Pref
NASDAQ:SOHOB
|
336.117x |
|
Gimat Magazacilik Sanayi ve Ticaret AS
IS:GMTAS
|
0.023x |
|
Kyung Nam Pharm Co Ltd
KQ:053950
|
-0.023x |
|
Next.e.GO N.V.
NASDAQ:EGOXF
|
-0.009x |
|
Rivco Australia Ltd
AU:RIV
|
-0.057x |
|
MIRIS HOLDING AB O.N.
F:9W4
|
N/A |
Annual Cash Flow Conversion Efficiency for Trevena Inc (2011–2023)
The table below shows the annual cash flow conversion efficiency of Trevena Inc from 2011 to 2023. For the full company profile with market capitalisation and key ratios, see TRVN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-7.66 Million | $-33.03 Million | 4.314x | +230.74% |
| 2022-12-31 | $15.60 Million | $-51.48 Million | -3.300x | -324.88% |
| 2021-12-31 | $64.63 Million | $-50.20 Million | -0.777x | -277.81% |
| 2020-12-31 | $104.07 Million | $-21.39 Million | -0.206x | +73.87% |
| 2019-12-31 | $30.08 Million | $-23.67 Million | -0.787x | -28.77% |
| 2018-12-31 | $41.53 Million | $-25.38 Million | -0.611x | +70.30% |
| 2017-12-31 | $34.63 Million | $-71.25 Million | -2.057x | -76.59% |
| 2016-12-31 | $78.58 Million | $-91.55 Million | -1.165x | -316.12% |
| 2015-12-31 | $143.13 Million | $-40.07 Million | -0.280x | +30.17% |
| 2014-12-31 | $99.20 Million | $-39.78 Million | -0.401x | +35.50% |
| 2013-12-31 | $38.99 Million | $-24.24 Million | -0.622x | -100.16% |
| 2012-12-31 | $-39.18K | $-14.81 Million | 377.866x | +43962.15% |
| 2011-12-31 | $15.42 Million | $-13.28 Million | -0.861x | -- |
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the… Read more